Bachem has shocked the pharmaceutical industry with its massive $2.3 billion acquisition of AmWiner, marking one of the largest deals in the Cagrillintide USA manufacturer peptide therapeutics sector this year. This strategic takeover signals Bachem's ambitious plans to dominate the growing market for peptide-based medications and expand its global